ALLISON CROSS: Open Payments
NPI 1427430917 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,154 in 103 payments from 16 companies in 2025. Trend: 2023 $489 · 2024 $877 · 2025 $2,154
Food & beverage: $2,154
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 17 | $435 |
| ABBVIE INC. | 16 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $276 |
| Gilead Sciences, Inc. | 8 | $224 |
| Ardelyx, Inc. | 12 | $183 |
| Intercept Pharmaceuticals, Inc. | 6 | $124 |
| QOL Medical, LLC | 6 | $115 |
| GENZYME CORPORATION | 5 | $113 |
| Ipsen Biopharmaceuticals, Inc | 5 | $112 |
| Regeneron Healthcare Solutions, Inc. | 2 | $56 |
Products named: REZDIFFRA, RINVOQ, ENTYVIO, IBSRELA, DUPIXENT, OCALIVA, Sucraid, IQIRVO.
Industry payments across LA — which companies pay providers there.
